CD73: an emerging checkpoint for cancer immunotherapy

Papers of special note have been highlighted as: • of interest

References

• 1. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol. Rev. 161, 95–109 (1998).
  Medline CASGoogle Scholar
• 2. Colgan SP, Eltzschig HK, Eckle T, Thompson LF. Physiological roles for ecto-5′-nucleotidase (CD73). Purinergic Signal. 2, 351–360 (2006).
  Medline CASGoogle Scholar
• 3. Horenstein AL, Chillemi A, Zaccarello G et al. A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology 2, e26246 (2013).
  MedlineGoogle Scholar
• 4. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916–920 (2001).
  Medline CASGoogle Scholar
• 5. Linden J. Adenosine in tissue protection and tissue regeneration. Mol. Pharmacol. 67, 1385–1387 (2005).
  Medline CASGoogle Scholar
• 6. Madara JL, Patapoff TW, Gillececastro B et al. 5′-adenosine monophosphate is the neutrophil-derived paracrine factor that elicits chloride secretion from T84 intestinal epithelial-cell monolayers. J. Clin. Invest. 91, 2320–2325 (1993).
  Medline CASGoogle Scholar
• 7. Eckle T, Krahn T, Grenz A et al. Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation 115, 1581–1590 (2007).
  Medline CASGoogle Scholar
• 8. Li QL, Price TP, Sundberg JP, Uitto J. Juxta-articular joint-capsule mineralization in CD73 deficient mice: similarities to patients with NT5E mutations. Cell Cycle 13, 2609–2615 (2014).
  Medline CASGoogle Scholar
• 9. Linden J, Cekic C. Regulation of Lymphocyte Function by Adenosine. Arterioscl. Throm. Vas. 32, 2097–2103 (2012).
  Medline CASGoogle Scholar
• 10. Zarek PE, Huang CT, Lutz ER et al. A(2A) receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111, 251–259 (2008).
  Medline CASGoogle Scholar
• 11. Eckle T, Faigle M, Grenz A, Laucher S, Thompson LF, Eltzschig HK. A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 111, 2024–2035 (2008).
  Medline CASGoogle Scholar
• 12. Novitskiy SV, Ryzhov S, Zaynagetdinov R et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 112, 1822–1831 (2008).
  Medline CASGoogle Scholar
• 13. Wilson JM, Ross WG, Agbai ON et al. The A(2B) adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J. Immunol. 182, 4616–4623 (2009).
  Medline CASGoogle Scholar
• 14. Ryzhov S, Novitskiy SV, Goldstein AE et al. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b(+)Gr1(+) cells. J.Immunol. 187, 6120–6129 (2011).
  Medline CASGoogle Scholar
• 15. Koscso B, Csoka B, Kokai E et al. Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages. J. Leukocyte Biol. 94, 1309–1315 (2013).
  MedlineGoogle Scholar
• 16. Ohta A, Gorelik E, Prasad SJ et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl Acad. Sci.USA 103, 13132–13137 (2006). • Paper showing the role of A2AR pathway in antitumor T cells, highlighting the therapeutic potential of A2AR inhibitors.
  Medline CASGoogle Scholar
• 17. Ryzhov S, Novitskiy SV, Zaynagetdinov R et al. Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia 10, 987–995 (2008).
  Medline CASGoogle Scholar
• 18. Wang L, Fan J, Thompson LF et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J. Clin.Invest. 121, 2371–2382 (2011).
  Medline CASGoogle Scholar
• 19. Stagg J, Beavis PA, Divisekera U et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 72, 2190–2196 (2012).
  Medline CASGoogle Scholar
• 20. Bowser JL, Blackburn MR, Shipley GL, Molina JG, Dunner K, Broaddus RR. Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. J. Clin. Invest. 126, 220–238 (2016).
  MedlineGoogle Scholar
• 21. Silverberg SG. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Modern Pathol. 13, 309–327 (2000).
  Medline CASGoogle Scholar
• 22. Allard D, Chrobak P, Allard B, Messaoudi N, Stagg J. Targeting the CD73-adenosine axis in immuno-oncology. Immunol. Lett. 205, 31–39 (2019).
  Medline CASGoogle Scholar
• 23. Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S et al. CD73 as a potential opportunity for cancer immunotherapy. Expert Opin. Ther. Targets 23, 127–142 (2019).
  Medline CASGoogle Scholar
• 24. Stagg J, Divisekera U, McLaughlin N et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl Acad. Sci. USA 107, 1547–1552 (2010). • The proof-of-concept study showing that anti-CD73 therapy improves adaptive antitumor immunity and inhibits metastasis of breast cancer.
  Medline CASGoogle Scholar
• 25. Jin D, Fan J, Wang L et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 70, 2245–2255 (2010). • Data demonstrating a potential mechanism for tumor CD73-mediated immune evasion and developing an immunotherapy strategy by targeting the enzymatic activity of CD73.
  Medline CASGoogle Scholar
• 26. Stagg J, Divisekera U, Duret H et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 71, 2892–2900 (2011).
  Medline CASGoogle Scholar
• 27. Yegutkin GG, Marttila-Ichihara F, Karikoski M et al. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur. J. Immunol. 41, 1231–1241 (2011).
  Medline CASGoogle Scholar
• 28. Zhi XL, Chen SF, Zhou P et al. RNA interference of ecto-5′-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin. Exp. Metastas. 24, 439–448 (2007).
  Medline CASGoogle Scholar
• 29. Zhou P, Zhi XL, Zhou TT et al. Overexpression of Ecto-5′-nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix. Cancer Biol. Ther. 6, 426–431 (2007).
  Medline CASGoogle Scholar
• 30. Wang L, Zhou XR, Zhou TT et al. Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J. Cancer Res. Clin. 134, 365–372 (2008).
  Medline CASGoogle Scholar
• 31. Zhi XL, Wang YJ, Zhou XR et al. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. Cancer Sci. 101, 2561–2569 (2010).
  Medline CASGoogle Scholar
• 32. Ujhazy P, Berleth ES, Pietkiewicz JM et al. Evidence for the involvement of ecto-5′-nucleotidase (CD73) in drug resistance. Int. J. Cancer 68, 493–500 (1996).
  Medline CASGoogle Scholar
• 33. Quezada C, Garrido W, Oyarzun C et al. 5′-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells. J. Cell. Physiol. 228, 602–608 (2013).
  Medline CASGoogle Scholar
• 34. Serra S, Horenstein AL, Vaisitti T et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 118, 6141–6152 (2011).
  Medline CASGoogle Scholar
• 35. Bavaresco L, Bernardi A, Braganhol E et al. The role of ecto-5′-nucleotidase/CD73 in glioma cell line proliferation. Mol.Cell. Biochem. 319, 61–68 (2008).
  Medline CASGoogle Scholar
• 36. Sadej R, Spychala J, Skladanowski AC. Expression of ecto-5′-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res. 16, 213–222 (2006).
  Medline CASGoogle Scholar
• 37. Spychala J, Lazarowski E, Ostapkowicz A, Ayscue LH, Jin A, Mitchell BS. Role of estrogen receptor in the regulation of ecto-5′-nucleotidase and adenosine in breast cancer. Clin. Cancer Res. 10, 708–717 (2004).
  Medline CASGoogle Scholar
• 38. Synnestvedt K, Furuta GT, Comerford KM et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110, 993–1002 (2002).
  Medline CASGoogle Scholar
• 39. Hart ML, Grenz A, Gorzolla IC, Schittenhelm J, Dalton JH, Eltzschig HK. Hypoxia-Inducible factor-1 alpha-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5′-nucleotidase (CD73) and the A2B adenosine receptor. J. Immunol. 186, 4367–4374 (2011).
  Medline CASGoogle Scholar
• 40. Robinson A, Keely S, Karhausen J, Gerich ME, Furuta GT, Colgan SP. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 134, 145–155 (2008).
  Medline CASGoogle Scholar
• 41. Eltzschig HK, Bratton DL, Colgan SP. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat. Rev. Drug Discov. 13, 852–869 (2014).
  Medline CASGoogle Scholar
• 42. Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 19, 355–367 (2013).
  Medline CASGoogle Scholar
• 43. Kiss J, Yegutkin GG, Koskinen K, Savunen T, Jalkanen S, Salmi M. IFN-beta protects from vascular leakage via up-regulation of CD73. Eur. J. Immunol. 37, 3334–3338 (2007).
  Medline CASGoogle Scholar
• 44. Spychala J, Zimmermann AG, Mitchell BS. Tissue-specific regulation of the ecto-5′-nucleotidase promoter – role of the cAMP response element site in mediating repression by the upstream regulatory region. J. Biol. Chem. 274, 22705–22712 (1999).
  Medline CASGoogle Scholar
• 45. Spychala J, Kitajewski J. Wnt and beta-catenin signaling target the expression of ecto-5′-nucleotidase and increase extracellular adenosine generation. Exp. Cell Res. 296, 99–108 (2004).
  Medline CASGoogle Scholar
• 46. Wang H, Lee S, Lo Nigro C et al. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Brit. J. Cancer 106, 1446–1452 (2012).
  Medline CASGoogle Scholar
• 47. Reinhardt J, Landsberg J, Schmid-Burgk JL et al. MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. Cancer Res. 77, 4697–4709 (2017).
  Medline CASGoogle Scholar
• 48. Liu L, Mayes PA, Eastman S et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin. Cancer Res. 21, 1639–1651 (2015).
  Medline CASGoogle Scholar
• 49. Kordass T, Osen W, Eichmuller SB. Controlling the immune suppressor: transcription factors and microRNAs regulating CD73/NT5E. Front. Immunol. 9, 813 (2018).
  MedlineGoogle Scholar
• 50. Zhou XR, Zhi XL, Zhou P et al. Effects of ecto-5′-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol. Rep. 17, 1341–1346 (2007).
  Medline CASGoogle Scholar
• 51. Rockenbach L, Bavaresco L, Farias PF et al. Alterations in the extracellular catabolism of nucleotides are involved in the antiproliferative effect of quercetin in human bladder cancer T24 cells. Urol. Oncol. 31, 1204–1211 (2013).
  Medline CASGoogle Scholar
• 52. Wang MX, Ren LM. Growth inhibitory effect and apoptosis induced by extracellular ATP and adenosine on human gastric carcinoma cells: involvement of intracellular uptake of adenosine. Acta Pharmacol. Sin. 27, 1085–1092 (2006).
  Medline CASGoogle Scholar
• 53. Shirali S, Aghaei M, Shabani M, Fathi M, Sohrabi M, Moeinifard M. Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3. Tumor Biol. 34, 1085–1095 (2013).
  Medline CASGoogle Scholar
• 54. Richard CL, Tan EY, Blay J. Adenosine upregulates CXCR4 and enhances the proliferative and migratory responses of human carcinoma cells to CXCL12/SDF-1 alpha. Int. J. Cancer 119, 2044–2053 (2006).
  Medline CASGoogle Scholar
• 55. Woodhouse EC, Amanatullah DF, Schetz JA, Liotta LA, Stracke ML, Clair T. Adenosine receptor mediates motility in human melanoma cells. Biochem. Bioph. Res. Co. 246, 888–894 (1998).
  Medline CASGoogle Scholar
• 56. Allard B, Turcotte M, Spring K, Pommey S, Royal I, Stagg J. Anti-CD73 therapy impairs tumor angiogenesis. Int. J. Cancer 134, 1466–1473 (2014).
  Medline CASGoogle Scholar
• 57. Kaplan HB. Methodological problems in the study of psychosocial influences on the AIDS process. Soc. Sci. Med. 29, 277–292 (1989).
  Medline CASGoogle Scholar
• 58. Song L, Ye W, Cui Y et al. Ecto-5′-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells. Oncotarget 8, 31977–31992 (2017).
  MedlineGoogle Scholar
• 59. Lupia M, Angiolini F, Bertalot G et al. CD73 regulates stemness and epithelial-mesenchymal transition in ovarian cancer-initiating cells. Stem Cell Rep. 10, 1412–1425 (2018).
  Medline CASGoogle Scholar
• 60. Zukowska P, Kutryb-Zajac B, Toczek M, Smolenski RT, Slominska EM. The role of ecto-5′-nucleotidase in endothelial dysfunction and vascular pathologies. Pharmacol. Rep. 67, 675–681 (2015).
  Medline CASGoogle Scholar
• 61. Wang L, Tang SX, Wang YJ et al. Ecto-5′-nucleotidase (CD73) promotes tumor angiogenesis. Clin. Exp. Metastas. 30, 671–680 (2013).
  Medline CASGoogle Scholar
• 62. Koszalka P, Pryszlak A, Golunska M et al. Inhibition of CD73 stimulates the migration and invasion of B16F10 melanoma cells in vitro, but results in impaired angiogenesis and reduced melanoma growth in vivo. Oncol. Rep. 31, 819–827 (2014).
  Medline CASGoogle Scholar
• 63. Koszalka P, Golunska M, Stanislawowski M et al. CD73 on B16F10 melanoma cells in CD73-deficient mice promotes tumor growth, angiogenesis, neovascularization, macrophage infiltration and metastasis. Int. J. Biochem. Cell B. 69, 1–10 (2015).
  Medline CASGoogle Scholar
• 64. Deaglio S, Dwyer KM, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257–1265 (2007).
  Medline CASGoogle Scholar
• 65. Romio M, Reinbeck B, Bongardt S, Huls S, Burghoff S, Schrader J. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. Am. J. Physiol.Cell Physiol. 301, C530–C539 (2011).
  Medline CASGoogle Scholar
• 66. Mandapathil M, Hilldorfer B, Szczepanski MJ et al. Generation and accumulation of immunosuppressive adenosine by human CD4(+)CD25(high)FOXP3(+) regulatory T cells. J. Biol. Chem. 285, 7176–7186 (2010).
  Medline CASGoogle Scholar
• 67. Mandapathil M, Szczepanski MJ, Szajnik M et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin. Cancer Res. 15, 6348–6357 (2009).
  Medline CASGoogle Scholar
• 68. Di Gennaro P, Gerlini G, Caporale R et al. T regulatory cells mediate immunosuppresion by adenosine in peripheral blood, sentinel lymph node and TILs from melanoma patients. Cancer Lett. 417, 124–130 (2018).
  MedlineGoogle Scholar
• 69. Sim GC, Martin-Orozco N, Jin L et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J. Clin. Invest. 124, 99–110 (2014).
  Medline CASGoogle Scholar
• 70. Schuler PJ, Saze Z, Hong CS et al. Human CD4(+)CD39(+) regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73(+) exosomes or CD73(+) cells. Clin. Exp. Immunol. 177, 531–543 (2014).
  Medline CASGoogle Scholar
• 71. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J. Immunol. 187, 676–683 (2011).
  Medline CASGoogle Scholar
• 72. Murata K, Tsukahara T, Emori M et al. Identification of a novel human memory T-cell population with the characteristics of stem-like chemo-resistance. Oncoimmunology 5, e1165376 (2016).
  MedlineGoogle Scholar
• 73. Toth I, Le AQ, Hartjen P et al. Decreased frequency of CD73(+) CD8(+) T cells of HIV-infected patients correlates with immune activation and T cell exhaustion. J. Leukocyte Biol. 94, 551–561 (2013).
  Medline CASGoogle Scholar
• 74. Flores-Santibanez F, Fernandez D, Meza D et al. CD73-mediated adenosine production promotes stem cell-like properties in mouse Tc17 cells. Immunology 146, 582–594 (2015).
  Medline CASGoogle Scholar
• 75. Bono MR, Fernandez D, Flores-Santibanez F, Rosemblatt M, Sauma D. CD73 and CD39 ectonucleotidases in T cell differentiation: beyond immunosuppression. Febs. Lett. 589, 3454–3460 (2015).
  Medline CASGoogle Scholar
• 76. Gourdin N, Bossennec M, Rodriguez C et al. Autocrine adenosine regulates tumor polyfunctional CD73(+)CD4(+) effector T cells devoid of immune checkpoints. Cancer Res. 78, 3604–3618 (2018).
  Medline CASGoogle Scholar
• 77. Chalmin F, Mignot G, Bruchard M et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 36, 362–373 (2012).
  Medline CASGoogle Scholar
• 78. Chatterjee S, Thyagarajan K, Kesarwani P et al. Reducing CD73 expression by IL1 beta-programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res. 74, 6048–6059 (2014).
  Medline CASGoogle Scholar
• 79. Buisseret L, Garaud S, Allard B et al. CD73 expression on tumor-infiltrating breast cancer leukocytes. Cancer Res. 75, Abstract nr 3361 (2015).
  Google Scholar
• 80. Wallace KL, Linden J. Adenosine A(2A) receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 116, 5010–5020 (2010).
  Medline CASGoogle Scholar
• 81. Beavis PA, Divisekera U, Paget C et al. Blockade of A(2A) receptors potently suppresses the metastasis of CD73(+) tumors. Proc. Natl Acad. Sci. USA 110, 14711–14716 (2013).
  Medline CASGoogle Scholar
• 82. Hausler SFM, del Barrio IM, Strohschein J et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol. Immun. 60, 1405–1418 (2011).
  MedlineGoogle Scholar
• 83. Raskovalova T, Lokshin A, Huang XJ, Jackson EK, Gorelik E. Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells – involvement of protein kinase A isozyme I (PKA I). Immunol. Res. 36, 91–99 (2006).
  Medline CASGoogle Scholar
• 84. Chambers AM, Wang J, Lupo KB, Yu H, Atallah Lanman NM, Matosevic S. Adenosinergic signaling alters natural killer cell functional responses. Front. Immunol. 9, 2533 (2018).
  MedlineGoogle Scholar
• 85. Hatfield SM, Kjaergaard J, Lukashev D et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci. Transl. Med. 7, 277ra30 (2015).
  MedlineGoogle Scholar
• 86. Mittal D, Young A, Stannard K et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 74, 3652–3658 (2014).
  Medline CASGoogle Scholar
• 87. Harish A, Hohana G, Fishman P, Arnon O, Bar-Yehuda S. A3 adenosine receptor agonist potentiates natural killer cell activity. Int. J. Oncol. 23, 1245–1249 (2003).
  Medline CASGoogle Scholar
• 88. Hamidzadeh K, Mosser DM. Purinergic signaling to terminate TLR responses in macrophages. Front. Immunol. 7, 74 (2016).
  MedlineGoogle Scholar
• 89. Cohen HB, Briggs KT, Marino JP, Ravid K, Robson SC, Mosser DM. TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses. Blood 122, 1935–1945 (2013).
  Medline CASGoogle Scholar
• 90. Zanin RF, Braganhol E, Bergamin LS et al. Differential macrophage activation alters the expression profile of NTPDase and Ecto-5′-nucleotidase. PLoS ONE 7, e31205 (2012).
  Google Scholar
• 91. Ponce NE, Sanmarco LM, Eberhardt N et al. CD73 inhibition shifts cardiac macrophage polarization toward a microbicidal phenotype and ameliorates the outcome of experimental chagas cardiomyopathy. J. Immunol. 197, 814–823 (2016).
  Medline CASGoogle Scholar
• 92. Eichin D, Laurila JP, Jalkanen S, Salmi M. CD73 activity is dispensable for the polarization of M2 macrophages. PLoSONE 10, e0134721 (2015).
  Google Scholar
• 93. de Haas N, de Koning C, Spilgies L, de Vries IJM, Hato SV. Improving cancer immunotherapy by targeting the STATe of MDSCs. Oncoimmunology 5, e1196312 (2016).
  Google Scholar
• 94. Ye C, Geng Z, Dominguez D et al. Targeting ornithine decarboxylase by alpha-difluoromethylornithine inhibits tumor growth by impairing myeloid-derived suppressor cells. J. Immunol. 196, 915–923 (2016).
  Medline CASGoogle Scholar
• 95. Ryzhov SV, Pickup MW, Chytil A et al. Role of TGF-beta signaling in generation of CD39(+)CD73(+) myeloid cells in tumors. J. Immunol. 193, 3155–3164 (2014).
  Medline CASGoogle Scholar
• 96. Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Blockade of A(2b) adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia 15, 1400-+ (2013).
  MedlineGoogle Scholar
• 97. Sorrentino C, Miele L, Porta A, Pinto A, Morello S. Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model. Oncotarget 6, 27478–27489 (2015).
  MedlineGoogle Scholar
• 98. Limagne E, Euvrard R, Thibaudin M et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res. 76, 5241–5252 (2016).
  Medline CASGoogle Scholar
• 99. Li JY, Wang LP, Chen XF et al. CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF–mTOR-HIF-1 signaling in patients with non-small cell lung cancer. Oncoimmunology 6, e1320011 (2017).
  Google Scholar
• 100. Li LF, Wang LP, Li JY et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res. 78, 1779–1791 (2018).
  Medline CASGoogle Scholar
• 101. Yamashita Y, Hooker SW, Jiang H et al. CD73 expression and fyn-dependent signaling on murine lymphocytes. Eur. J. Immunol. 28, 2981–2990 (1998).
  Medline CASGoogle Scholar
• 102. Anderson SM, Tomayko MM, Ahuja A, Haberman AM, Shlomchik MJ. New markers for murine memory B cells that define mutated and unmutated subsets. J. Exp. Med. 204, 2103–2114 (2007).
  Medline CASGoogle Scholar
• 103. Tomayko MM, Steinel NC, Anderson SM, Shlomchik MJ. Cutting edge: hierarchy of maturity of murine memory B cell subsets. J. Immunol. 185, 7146–7150 (2010).
  Medline CASGoogle Scholar
• 104. Forte G, Sorrentino R, Montinaro A et al. Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J. Immunol. 189, 2226–2233 (2012).
  Medline CASGoogle Scholar
• 105. Turcotte M, Spring K, Pommey S et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 75, 4494–4503 (2015).
  Medline CASGoogle Scholar
• 106. Koivisto M, Tervahartiala M, Kenessey I, Jalkanen S, Bostrom PJ, Salmi M. Cell-type specific CD73 expression is an independent prognostic factor in bladder cancer. Carcinogenesis 40, 84–92 (2018).
  Google Scholar
• 107. Costa A, Kieffer Y, Scholer-Dahirel A et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33, 463–479 e410 (2018).
  Medline CASGoogle Scholar
• 108. Givel AM, Kieffer Y, Scholer-Dahirel A et al. miR200-regulated CXCL12 beta promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat. Commun. 9, 1056 (2018).
  MedlineGoogle Scholar
• 109. Leclerc BG, Charlebois R, Chouinard G et al. CD73 expression is an independent prognostic factor in prostate cancer. Clin. Cancer Res. 22, 158–166 (2016).
  Medline CASGoogle Scholar
• 110. Terp MG, Olesen KA, Arnspang EC et al. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J. Immunol. 191, 4165–4173 (2013).
  Medline CASGoogle Scholar
• 111. Braganhol E, Tamajusuku AS, Bernardi A, Wink MR, Battastini AM. Ecto-5′-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line. Biochim. Biophys. Acta 1770, 1352–1359 (2007).
  Medline CASGoogle Scholar
• 112. Xiong L, Wen Y, Miao XY, Yang ZL. NT5E and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer. Cell Tissue Res. 355, 365–374 (2014).
  Medline CASGoogle Scholar
• 113. Jadidi-Niaragh F, Atyabi F, Rastegari A et al. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice. J. Control. Rel. 246, 46–59 (2017).
  Medline CASGoogle Scholar
• 114. Ghalamfarsa G, Rastegari A, Atyabi F et al. Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice. J. Cell Physiol. 233, 7165–7177 (2018).
  Medline CASGoogle Scholar
• 115. Young A, Ngiow SF, Barkauskas DS et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell. 30, 391–403 (2016). • Paper showing the nonredundant activity of CD73 and A2AR inhibition to promote therapeutic response by coblockade of adenosine signaling in leukocytes.
  Medline CASGoogle Scholar
• 116. Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer Res. 19, 5626–5635 (2013). • The first preclinical study indicating a synergistic combination of anti-CD73 mAb and blockade of CTLA-4 and PD-1.
  Medline CASGoogle Scholar
• 117. Beavis PA, Milenkovski N, Henderson MA et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol. Res. 3, 506–517 (2015).
  Medline CASGoogle Scholar
• 118. Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am. J. Cancer Res. 4, 172–181 (2014).
  MedlineGoogle Scholar
• 119. Hay CM, Sult E, Huang QH et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology 5, e1208875 (2016).
  MedlineGoogle Scholar
• 120. Beavis PA, Henderson MA, Giuffrida L et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J. Clin. Invest. 127, 929–941 (2017).
  MedlineGoogle Scholar
• 121. Wang J, Lupo KB, Chambers AM, Matosevic S. Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells. J. Immunother. Cancer 6, 136 (2018).
  MedlineGoogle Scholar
• 122. Chen S, Fan J, Zhang M et al. CD73 expression on effector T cells sustained by TGF-beta facilitates tumor resistance to anti-4-1BB/CD137 therapy. Nat. Comm. 10, 150 (2019). • The first preclinical study indicating a synergistic combination of anti-CD73 mAb and agonist anti-4-1BB or anti-GITR therapy.
  MedlineGoogle Scholar
• 123. Galli U, Travelli C, Massarotti A et al. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. J. Med. Chem. 56, 6279–6296 (2013).
  Medline CASGoogle Scholar
• 124. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol. Metab. 20, 130–138 (2009).
  Medline CASGoogle Scholar
• 125. Grozio A, Sociali G, Sturla L et al. CD73 protein as a source of extracellular precursors for sustained NAD(+) biosynthesis in FK866-treated tumor cells. J. Biol.Chem. 288, 25938–25949 (2013).
  Medline CASGoogle Scholar
• 126. Garavaglia S, Bruzzone S, Cassani C et al. The high-resolution crystal structure of periplasmic Haemophilus influenzae NAD nucleotidase reveals a novel enzymatic function of human CD73 related to NAD metabolism. Biochem. J. 441, 131–141 (2012).
  Medline CASGoogle Scholar
• 127. Sociali G, Raffaghello L, Magnone M et al. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model. Oncotarget 7, 2968–2984 (2016).
  MedlineGoogle Scholar
• 128. Turcotte M, Allard D, Mittal D et al. CD73 promotes resistance to HER2/ErbB2 antibody therapy. Cancer Res. 77, 5652–5663 (2017).
  Medline CASGoogle Scholar
• 129. Young A, Ngiow SF, Madore J et al. Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis. Cancer Res. 77, 4684–4696 (2017).
  Medline CASGoogle Scholar
• 130. Antonioli L, Novitskiy SV, Sachsenmeier KF, Fornai M, Blandizzi C, Hasko G. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discov. Today 22, 1686–1696 (2017).
  Medline CASGoogle Scholar
• 131. Loi S, Pommey S, Haibe-Kains B et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc.Natl Acad. Sci. USA 110, 11091–11096 (2013).
  Medline CASGoogle Scholar
• 132. Wennerberg E, Formenti S, Demaria S. Adenosine regulates radiation therapy-induced anti-tumor immunity. Int. J. Radiat. Oncol. 96, S126–S127 (2016).
  Google Scholar
• 133. Allard D, Allard B, Gaudreau PO, Chrobak P, Stagg J. CD73-adenosine: a next-generation target in immuno-oncology. Immunotherapy 8, 145–163 (2016).
  CASGoogle Scholar
• 134. Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Hasko G. Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer 2, 95–109 (2016).
  MedlineGoogle Scholar
• 135. Buisseret L, Pommey S, Allard B et al. Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial. Cancer Res. 78, (2018).
  Google Scholar
• 136. Reinhardt J, Landsberg J, Schmid-Burgk JL et al. MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. Cancer Res. 77, 4697–4709 (2017).
  Medline CASGoogle Scholar
• 137. Geoghegan JC, Diedrich G, Lu X et al. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action. mAbs. 8, 454–467 (2016). • Analysis of the properties of the first antihuman CD73 monoclonal antibody that is currently tested in clinical trials.
  Medline CASGoogle Scholar
• 138. Overman MJ, LoRusso P, Strickler JH, Patel SP, Clarke SJ, Noonan AM. Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc). J. Clin. Oncol. 36, Abstract no. 4123 (2018).
  MedlineGoogle Scholar
• 139. Barnhart BC, Sega E, Yamniuk A et al. A therapeutic antibody that inhibits CD73 activity by dual mechanisms. Cancer Res. 76, Abstract no. 1476 (2016).
  Google Scholar
• 140. Lorenzen S, Siu LL, Burris H et al. Preliminary Phase Iprofile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors. Oncol.Res. Treat. 41, 263–263 (2018).
  Google Scholar
• 141. Gong YP, Wan RZ, Liu ZP. Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings. Expert Opin. Ther. Pat. 28, 167–171 (2018).
  Medline CASGoogle Scholar
• 142. Kenneth LJ, Lawson V, Jeffrey JL et al. Discovery and characterization of AB680, a potent and selective small-molecule CD73 inhibitor for cancer immunotherapy [abstract]. Cancer Res. 78, Abstract no. 1756 (2018).
  Google Scholar
• 143. Becker NNA, Yin F, Zhang K et al. CD73 inhibitors (CD73i) reverse the AMP/adenosine-mediated impairment of immune effector cell activation by immune checkpoint inhibitors (ICI) [abstract]. Cancer Res. 78, Abstract no. 710 (2018).
  MedlineGoogle Scholar
• 144. Tang J, Pearce L, O'Donnell-Tormey J, Hubbard-Lucey VM. Trends in the global immuno-oncology landscape. Nat. Rev. Drug Discov. 17, 783–784 (2018).
  Medline CASGoogle Scholar
• 145. Pettengill M, Robson S, Tresenriter M et al. Soluble ecto-5′-nucleotidase (5′-NT), alkaline phosphatase, and adenosine deaminase (ADA1) activities in neonatal blood favor elevated extracellular adenosine. J. Biol. Chem. 288, 27315–27326 (2013).
  Medline CASGoogle Scholar
• 146. Maksimow M, Kyhala L, Nieminen A et al. Early prediction of persistent organ failure by soluble CD73 in patients with acute pancreatitis*. Crit. Care Med. 42, 2556–2564 (2014).
  Medline CASGoogle Scholar
• 147. Vaara ST, Hollmen M, Korhonen AM et al. Soluble CD73 in critically Ill septic patients – data from the prospective FINNAKI study. PLoSONE 11, e0164420 (2016).
  Google Scholar
• 148. Morello S, Capone M, Sorrentino C et al. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. J. Transl.Med. 15, 244 (2017).
  MedlineGoogle Scholar
• 149. Aghaei M, Karami-Tehrani F, Salami S, Atri M. Diagnostic value of adenosine deaminase activity in benign and malignant breast tumors. Arch. Med. Res. 41, 14–18 (2010).
  Medline CASGoogle Scholar
• 150. Aghaei M, Karami-Tehrani F, Salami S, Atri M. Adenosine deaminase activity in the serum and malignant tumors of breast cancer: the assessment of isoenzyme ADA1 and ADA2 activities. Clin. Biochem. 38, 887–891 (2005).
  Medline CASGoogle Scholar
• 151. Sadej R, Skladanowski AC. Dual, enzymatic and non-enzymatic, function of ecto-5′-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells. Acta Biochim. Pol. 59, 647–652 (2012).
  Medline CASGoogle Scholar
• 152. Sadej R, Inail K, Rajfur Z et al. Tenascin C interacts with Ecto-5′-nucleotidase (eN) and regulates adenosine generation in cancer cells. Biochim. Biophys. Acta 1782, 35–40 (2008).
  Medline CASGoogle Scholar
• 153. Jiang T, Xu X, Qiao M et al. Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers. BMC Cancer 18, 267 (2018).
  MedlineGoogle Scholar
• 154. Leclerc BG, Charlebois R, Chouinard G et al. CD73 expression is an independent prognostic factor in prostate cancer. Clin. Cancer Res. 22, 158–166 (2016).
  Medline CASGoogle Scholar
• 155. Buisseret L, Pommey S, Allard B et al. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a Phase III clinical trial. Ann. Oncol. 29, 1056–1062 (2018).
  Medline CASGoogle Scholar